Cleerly

“And so then you go through this effort and this is probably, I've just described the 10 to 15 year effort here to get to that point.”

“Like, if you include the in-kind support, like, it's well over two hundred million dollars to do this trial.”

“Yeah, I mean, we've done a blended, a compounded annual growth of about a little over a hundred percent over the last five years, and so we've been doubling, more than doubling every year, which is great.”

“We're doing a large-scale randomized control trial right now. It's about 7500 patients. We're a little over 2000 patients enrolled, and the purpose of this trial is to test the hypothesis that image-guided care, clearly guided care, is superior to conventional…”

“There's, you know, a number of studies that we've done as a company that have validated our technologies against every invasive catheter that you could think of to prove that, like, what we're seeing is actually the disease that the interventional or the invas…”

“We hired 20 technologists, CT technologists who had gone to radiographic imaging school, and they were the ones who were tracing out all of the images so that we could quantify and characterize the amount and the type of plaque that there was. It was taking th…”

“I think, I forget exactly how many patients we've done in total, but it's probably got to be close to a 100,000 at this point in time, so somewhere in that range or so.”

“So the Series C round came together with Fidelity and T. Rowe Price. Pablo Srugo: How much was that? Dr. Jim: that was about two hundred twenty-five million.”

“I mean, during the pandemic, right, like, we were 17 days away from being out of operating capital.”

“When something has too many factors that are contributing to the disease, I think that the best way to do it is to find a single metric that integrates the lifetime exposure of That, to that, of that individual, to all of those known and unknown risk factors, …”